CA2134611C - Process for preparing solid pharmaceutical dosage forms - Google Patents

Process for preparing solid pharmaceutical dosage forms Download PDF

Info

Publication number
CA2134611C
CA2134611C CA002134611A CA2134611A CA2134611C CA 2134611 C CA2134611 C CA 2134611C CA 002134611 A CA002134611 A CA 002134611A CA 2134611 A CA2134611 A CA 2134611A CA 2134611 C CA2134611 C CA 2134611C
Authority
CA
Canada
Prior art keywords
solvent
pharmaceutically active
active substance
process according
units
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002134611A
Other languages
French (fr)
Other versions
CA2134611A1 (en
Inventor
Richard John Yarwood
Patrick Kearney
Andrew Roy Thompson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Catalent Pharma Solutions Inc
Original Assignee
Catalent Pharma Solutions Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to GB9421837A priority Critical patent/GB9421837D0/en
Application filed by Catalent Pharma Solutions Inc filed Critical Catalent Pharma Solutions Inc
Priority to CA002134611A priority patent/CA2134611C/en
Priority to US08/330,936 priority patent/US5738875A/en
Priority to PT95934712T priority patent/PT737065E/en
Priority to AT95934712T priority patent/ATE198150T1/en
Priority to CNB95191538XA priority patent/CN1204877C/en
Priority to PCT/GB1995/002486 priority patent/WO1996013252A1/en
Priority to JP51437996A priority patent/JP3839845B2/en
Priority to ES95934712T priority patent/ES2153498T3/en
Priority to DK95934712T priority patent/DK0737065T3/en
Priority to MX9602514A priority patent/MX9602514A/en
Priority to AU37028/95A priority patent/AU3702895A/en
Priority to EP95934712A priority patent/EP0737065B1/en
Priority to DE69519664T priority patent/DE69519664T2/en
Priority to ZA959073A priority patent/ZA959073B/en
Publication of CA2134611A1 publication Critical patent/CA2134611A1/en
Priority to GR20010400012T priority patent/GR3035194T3/en
Application granted granted Critical
Publication of CA2134611C publication Critical patent/CA2134611C/en
Priority to JP2005370451A priority patent/JP2006111635A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D25/00—Filters formed by clamping together several filtering elements or parts of such elements
    • B01D25/12—Filter presses, i.e. of the plate or plate and frame type
    • B01D25/176—Filter presses, i.e. of the plate or plate and frame type attaching the filter element to the filter press plates, e.g. around the central feed hole in the plates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A process for the preparation of an oral solid rapidly disintegrating dosage form of a pharmaceutically active substance which has an unacceptable taste which process comprises forming a solution or a suspension in a solvent of a form of the pharmaceutically active substance which is less soluble in water and more palatable than the form with the unacceptable taste together with a water-soluble or water-dispersible carrier material, forming discrete units of the suspension or solution and removing the solvent from the discrete units under conditions whereby a network of the carrier material carrying a dosage of the less soluble and more palatable form of the pharmaceutically active substance is formed.

Description

PROCESS FOR PREPARING SOLID
PHARMACEUTICAL DOSAGE FORMS
The present invention relates to a process for preparing solid pharmaceutical dosage forms and, in particular, to a process for preparing an oral solid rapidly disintegrating dosage form of a pharmaceutically active substance which has an unacceptable taste to a human being or to an animal.
Many pharmaceutically active substances are presented for oral administration in the form of tablets, pills or capsules. The tablet, pill or capsule generally has to be swallowed with water so that the pharmaceutically active substance can be absorbed via the gastro-intestinal tract. For some patients swallowing the tablet, pill or capsule is difficult or impossible and this is particularly the case for paediatric patients and geriatric patients. A
similar difficulty is often encountered when trying to administer tablets to non-human animals which may be uncooperative in taking tablets, pills or capsules.
Oral solid pharmaceutical dosage forms which rapidly disintegrate in the mouth and methods for their preparation have been proposed in GH-A-1548022 and GB-A-2111423. The solid dosage forms as disclosed comprise an open matrix network carrying the pharmaceutically active substance, the open matrix comprising a water-soluble or water-dispersible carrier material which is inert towards the pharmaceutically active substance. The solid dosage forms are prepared by the sublimation or removal of solvent from a solution or suspension comprising the pharmaceutically active substance and the carrier material. Sublimation or removal of solvent is preferably carried out by freeze drying.
Other methods for the preparation of oral solid pharmaceutical dosage forms which rapidly disintegrate in the mouth are disclosed in US-A-5039540, US-A-5120549, US-A-5330763, WO 93/12769 and WO 94/14422.
The solid dosage forms which are produced by these various methods rapidly disintegrate on being placed in the mouth of the patient, thereby delivering the desired dose of the pharmaceutically active substance.
Although the solid dosage forms as described above overcome the problem of swallowing tablets, pills or capsules, the patient will taste the pharmaceutically active substrate as the dosage form disintegrates. For some pharmaceutically active substances the taste, if slightly unpleasant, can be rendered acceptable by the use of sweetening agents or flavouring agents which mask the taste. However, for some pharmaceutically active substances an unpalatable product will still be produced, despite the use of sweetening agents and flavouring agents, which decreases patient compliance.
We have now developed a method for the preparation of an oral solid rapidly disintegrating dosage form of a pharmaceutically active substance which has an unacceptable taste which does not only depend upon trying to mask the unacceptable taste by the use of sweetening agents, flavouring agents and the like.
Accordingly, the present invention provides a process for the preparation of an oral solid rapidly disintegrating dosage form of a pharmaceutically active substance which has an unacceptable taste, which process comprises forming a solution or a suspension in a solvent of a form of the pharmaceutically active substance which is less soluble in water than the form with the unacceptable 2134~~~.
taste together with a water-soluble or water-dispersible carrier material, forming discrete units of the solution or suspension removing the solvent from the discrete units under conditions and whereby a network of the carrier material carrying a unit dosage of the less soluble form of the pharmaceutically active substance is formed.
By the term "rapidly disintegrating" as used herein is meant that the solid dosage form will disintegrate in water at 37°C in 60 seconds or less, preferably 5 to 10 seconds or less when tested by the following procedure which is analogous to the Disintegration Test for Tablets, B.P. 1973 and which is described in British Patent No. 1548022:-Apparatus A glass or suitable plastic tube 80 to 100 mm long, with an internal diameter of about 28 mm and an external diameter of 30 to 31 mm, and fitted at the lower end, so as to form a basket, with a disc of rustproof wire gauze complying with the requirements for a No. 1.70 sieve (B. P. 1973 page A136).
A glass cylinder with a flat base and an internal diameter of about 45 mm containing water and not less than 15 cm deep at a temperature between 36o and 38°C.
The basket is suspended centrally in the cylinder in such a way that it can be raised and lowered repeatedly in a uniform manner so that at the highest position the gauze just breaks the surface of the water and at the lowest position the upper rim of the basket just remains clear of the water.
Method Place one shaped article in the basket and raise and lower it in such a manner that the complete up and down movement is repeated at a rate equivalent to thirty times a minute. The shaped articles are disintegrated when no particle remains above the gauze which would not readily pass through it.
On oral administration of the solid dosage form of the invention to a patient the pharmaceutical dosage form rapidly disintegrates in the mouth.
The oral rapidly disintegrating solid dosage form of the present invention enables poorly tasting pharmaceutically active substances to be presented in a palatable form without changing the bioavailability of the pharmaceutically active substance relative to an existing marketed solid dosage form containing the more soluble compound. The pharmaceutically active substance is presented as a less soluble form rendering less of the drug to be tasted as the solid dosage form dissolves/disintegrates in saliva.
The pharmaceutically active substance with the unacceptable taste may be presented in less soluble form prior to formation of the said solution or suspension. Alternatively, the pharmaceutically active form may be converted into the less soluble form during the process of the invention, for example during the preparation of the solution or suspension.
The pharmaceutically active substance with the unacceptable taste may be rendered less soluble by conversion of a salt to a free acid or a free base, changing the salt form, formation of a hydrate, or changing the polymorphic form thereof, or by any other suitable means.
The discrete units of the suspension or solution may be in the form of liquid units, for example contained within the pockets of a suitable mould, solid units, for example frozen units, or gelled units where the carrier material readily forms a gel.

213~~1I
~ 5 -The removal of solvent from the discrete units of the solution or suspension comprising the pharmaceutically active substance in its less soluble form and a water-soluble or water-dispersible carrier material is carried out by techniques well known to those skilled in the art.
When the discrete units are in liquid form they will generally be frozen or gelled prior to drying.
The liquid solution or suspension which may be contained within the pockets of a suitable mould is frozen, for example by passing a gaseous cooling medium, such as liquid nitrogen over the mould, or by inserting the mould into a nitrogen spray freezing chamber, or cooling by passing the mould over a cold surface. Once the dosage forms have been frozen, the mould may be stored in a cold store, prior to drying.
Frozen discrete units may be dried by freeze drying according to techniques which are well known in the art. The solvent is sublimed in a freeze drying process under a reduced pressure which transforms the solid solvent directly into a vapour. The freeze drying process will generally be carried out in a freeze drying chamber typically operating under a vacuum of 0.1 to 1.0 mBar for a period of time of from 180 to 500 minutes.
Alternatively, frozen discrete units may be dried by a process as described in US Patents Nos.
5120549 and 5330763. In this method the pharmaceutically active substance and carrier material dispersed in a first solvent is solidified and the solidified matrix is subsequently contacted with a second solvent that is substantially miscible with the first solvent at a temperature lower than the solidification point of the first solvent, the matrix component being substantially insoluble in the second solvent, the first solvent thereby being removed from the matrix.
Another alternative process for drying frozen discrete units is described in W094/14422. In this process the solvent is removed under conditions whereby the solvent is evaporated from the solid through the liquid phase to a gas, rather than subliming from a solid to a gas as in lyophilization.
This is achieved by vacuum drying at a temperature below the equilibrium freezing point of the composition at which point the solvent (such as water) changes phase.
When the discrete units are gelled units, any drying methods can be used which do not affect the properties of the preparations. For example, drying may be carried out at decreased pressure, or by forced-air drying. Drying at decreased pressure is preferably carried out at a temperature of from 25°
to 35°C under a vacuum of -750mm Hg or less, for 2 to 5 hours, whilst drying using forced-air drying is preferably carried out at a temperature of from 3°
to 15°C for 1 to 6 days.
The solvent used in forming the solution or suspension of the pharmaceutically active substance is preferably water but it may be admixed with a co-solvent, such as alcohol, if it is desired to improve the solubility of the active substance.
The carrier material which is used to form the network containing the pharmaceutically active substance may be any water-soluble or water-dispersible material that is pharmaceutically acceptable, inert to the pharmaceutically active substance and which is capable of forming a rapidly disintegrating network. The preferred carrier material for use in the present invention is gelatin, preferably pharmaceutical grade gelatin.
Other materials may also be used, for example hydrolysed dextrose, dextran, dextrin, maltodextrin, alginates, hydroxyethylcellulose, sodium carboxymethylcellulose, microcrystalline cellulose, corn-syrup solids, pectin, carrageenan, agar, chitosan, locust bean gum, xanthan gum, guar gum, acacia gum, tragacanth, konjac flour, rice flour, wheat gluten, sodium starch glycolate, soy fibre protein, potato protein, papain, horse radish peroxidase, glycine or mannitol.
l0 The suspension or solution prepared according to the process of the present invention is preferably formed into discrete units by introduction into a mould which preferably comprises a plurality of depressions, each depression being of the desired shape and size for the oral dosage form product. The mould preferably comprises a plurality of depressions formed in a sheet of a filmic material which may be similar to the material employed conventionally in the blister packaging of pharmaceuticals. A particularly preferred filmic material for use as a mould in the present invention is described in W094/12142. The desired quantities of the suspension or solution may be filled into the mould using an automatic filling means which delivers a predetermined dose into each of the depressions in the mould.
A covering material may be adhered to the filmic material in the area surrounding the depressions after the removal of solvent from the solution or suspension filling the depressions. The covering sheet is preferably an aluminium foil or aluminium foil laminate which may be adhered to the filmic material around the depressions by, for example a heat sensitive material. The cover sheet may be adhered to the filmic material in a manner such that it can be peeled away by the user to uncover the oral dosage form in the depression in the mould or, alternatively, ~~34~~~
_$_ it may be adapted for the oral dosage forms to be pushed through.
Alternative methods of forming discrete frozen or gelled units of the solution or suspension include solidifying the mixtures in dropwise fashion. For example, the solution or suspension may be passed through one or more holes to form drops, spheres or a spray of small particles which can be solidified by passage through a cold gas or liquid, for example liquid nitrogen. Alternatively, the drops, spheres or spray may be solidified by contact with a chilled liquid which is immiscible with the solution or suspension and which has a density such that the drops either fall through the immiscible liquid as they solidify, or float on the surface of the immiscible liquid.
The suspension or solution prepared in accordance with the process of the present invention may also contain other additional ingredients such as colouring agents, flavouring agents, sweetening agents or preservatives, or fillers such as mannitol or sorbitol which improve the physical properties of the oral dosage form.
The process of the present invention may be used to prepare oral solid rapidly disintegrating dosage forms of various pharmaceutically active substances which have an unacceptable taste. For example, loperamide is incorporated into conventional tablets in the form of its hydrochloride which has an unacceptable taste for formulation into an oral rapidly disintegrating dosage form. However, the use of loperamide in the form of the free base enables a palatable formulation to be produced. Similarly, domperidone is incorporated into conventional tablets in the form of its maleate which has an unacceptable taste for formulation into an oral rapidly - ~ 213~~11 disintegrating dosage form. However, the use of domperidone in the form of the free base enables a palatable formulation to be produced.
An advantage of the use of the less soluble forms of the pharmaceutically active substances in the process of the present invention is that the less soluble forms are generally easier to freeze dry, vacuum dry or dry conventionally.
The process of the present invention for making more palatable oral rapidly disintegrating dosage forms obviates the need to use costly drug coating techniques or complexation techniques to mask the taste of the pharmaceutically active substance.
The present invention also includes within its scope the oral solid rapidly disintegrating dosage forms prepared according to the process of the invention.
Accordingly, the present invention includes within its scope an oral solid rapidly disintegrating dosage form of a pharmaceutically active substance which has been rendered more palatable by the process as described above.
The present invention will be further described with reference to the following Examples.

An oral solid rapidly disintegrating dosage form of loperamide was prepared from loperamide hydrochloride as follows:
Inqredients Quantities for 400 units Loperamide hydrochloride 0.800 g Gelatin 2.345 g Mannitol 1.759 g Aspartame 0.300 g Mint flavour 0.120 g Sodium hydrogen carbonate 0.150 g Purified water 54.526 g The gelatin was added to water in a mixing bowl and heated with mixing to approximately 40°C. The mixture was mixed and homogenized under vacuum until dissolution of the gelatin was complete.
The gelatin solution was added to a mixture of mannitol, sodium hydrogen carbonate and loperamide hydrochloride and the mixture mixed and homogenised until the soluble components had dissolved and the dispersion of the drug particles was complete. The mixture was cooled under vacuum and aspartame and mint flavour added thereto.
The suspension was dosed into blister pockets, frozen and freeze dried to produce the final dosage form.
During the processing the loperamide hydrochloride was converted into the less soluble loperamide free base form by the sodium hydrogen carbonate buffer.

21'~~~:~1 The product had an acceptable taste.

Domperidone maleate is a poor tasting pharmaceutical compound and when initially formulated as a freeze dried rapidly disintegrating oral dosage form, produced an unacceptable product.
Domperidone was formulated in the form of the free base (which is less soluble in water or saliva than domperidone maleate) into an oral solid rapidly disintegrating dosage form using the following ingredients.
Ingredients Weight per Unit Domperidone 10 mg Aspartame 0.75 mg Peppermint flavour 0.15 mg Gelatin 5.70 mg Mannitol 5.20 mg Purified water 128.20 mg A solution containing the gelatin and mannitol was prepared and to this were added the aspartame and peppermint flavour. Aliquots of the resulting solution were added to the domperidone powder and a paste formed on stirring. The remainder of the solution was added and homogeneous suspension obtained. The suspension was dispensed in 150 mg aliquots into the pockets of a blister pack, frozen and freeze dried to produce the final dosage form.
The product had an acceptable taste.

Claims (23)

1. A process for the preparation of an oral solid rapidly disintegrating dosage form of a pharmaceutically active substance which has an unacceptable taste which process comprises forming a system selected from the group consisting of a solution and a suspension in a solvent of a form of the pharmaceutically active substance which is less soluble in water and more palatable than the form with the unacceptable taste together with a carrier material selected from the group consisting of water-soluble and water-dispersible carrier materials, forming discrete units of the system and removing the solvent from the discrete units under conditions whereby a network of the carrier material carrying a dosage of the less soluble and more palatable form of the pharmaceutically active substance is formed.
2. Process according to claim 1 wherein the pharmaceutically active substance with the unacceptable taste is presented in a less soluble form prior to formation of the said system.
3. Process according to claim 1 wherein the pharmaceutically active substance with the unacceptable taste is converted into a less soluble form during the preparation of the system.
4. Process according to claim 1 wherein the pharmaceutically active substance is rendered less soluble by a method selected from the group consisting of conversion of a salt to a free acid, conversion of a salt to a free base, changing the salt form, formation of a hydrate, and changing the polymorphic form thereof.
5. Process according to any one of claims 1 to 4 wherein the solvent comprises water.
6. Process according to claim 6 wherein the water contains a co-solvent.
7. Process according to any one of claims 1 to 6 wherein the carrier material is gelatin.
8. Process according to any one of claims 1 to 7 wherein the discrete units are selected from the group consisting of liquid, frozen and gelled units.
9. Process according to claim 8 wherein the discrete units are formed in a mould comprising a plurality of pockets.
10. Process according to claim 8 wherein the discrete units are liquid units which are frozen prior to removal of the solvent.
11. Process according to claim 8 or claim 9 wherein the units are frozen units and the solvent is removed by freeze drying.
12. Process according to claim 8 wherein the units are frozen units and the solvent is removed by contacting the frozen matrix comprising the first solvent, the pharmaceutically active substance and the carrier material with a second solvent that is substantially miscible with the first solvent at a temperature lower than the solidification point of the first solvent, whereby the first solvent is removed from the matrix.
13. Process according to claim 8 wherein the units are frozen units and the solvent is removed by vacuum drying under conditions whereby the solvent is evaporated from the frozen units through the liquid phase to a gas.
14. Process according to claim 8 wherein the discrete units are gelled units from which the solvent is removed by drying under conditions selected from the group consisting of decreased pressure and forced-air drying.
15. Process according to claim 9 wherein the mould comprises at least one depression in a sheet of a filmic material.
16. Process according to claim 15 wherein a sheet of a covering material is adhered to the filmic material in the area around the at least one depression after the removal of solvent from the system.
17. Process according to any one of claims 1 to 16 wherein the pharmaceutically active substance is loperamide hydrochloride which is converted into the form of the loperamide free base during the preparation of the system.
18. Process according to any one of claims 1 to 16 wherein the less soluble pharmaceutically active substance is free domperidone base.
19. An oral solid rapidly disintegrating dosage form of a pharmaceutically active substance whenever prepared by a process according to any one of claims 1 to 16.
20. An oral solid rapidly disintegrating dosage form according to claim 19 wherein the pharmaceutically active substance is loperamide which is present in the composition in the form of the loperamide free base.
21. An oral solid rapidly disintegrating dosage form according to claim 19 wherein the pharmaceutically active substance is domperidone which is present in the composition in the form of the domperidone free base.
22. An oral solid rapidly disintegrating dosage form comprising loperamide free base as the pharmaceutically active substance in a network of a carrier material selected from the group consisting of water-soluble and water-dispersible carrier materials.
23. An oral solid rapidly disintegrating dosage form comprising domperidone free base as the pharmaceutically active substance in a network of a carrier material selected from the group consisting of water-soluble and water-dispersible carrier materials.
CA002134611A 1994-10-28 1994-10-28 Process for preparing solid pharmaceutical dosage forms Expired - Lifetime CA2134611C (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
CA002134611A CA2134611C (en) 1994-10-28 1994-10-28 Process for preparing solid pharmaceutical dosage forms
US08/330,936 US5738875A (en) 1994-10-28 1994-10-28 Process for preparing solid pharmaceutical dosage forms
GB9421837A GB9421837D0 (en) 1994-10-28 1994-10-28 Process for preparing solid pharmaceutical dosage forms
EP95934712A EP0737065B1 (en) 1994-10-28 1995-10-20 Process for preparing solid pharmaceutical dosage forms
CNB95191538XA CN1204877C (en) 1994-10-28 1995-10-20 Process for preparing solid pharmaceutical dosage forms
PCT/GB1995/002486 WO1996013252A1 (en) 1994-10-28 1995-10-20 Process for preparing solid pharmaceutical dosage forms
JP51437996A JP3839845B2 (en) 1994-10-28 1995-10-20 Solid medicinal preparation form
ES95934712T ES2153498T3 (en) 1994-10-28 1995-10-20 PROCESS TO PREPARE SOLID PHARMACEUTICAL DOSAGE FORMS.
PT95934712T PT737065E (en) 1994-10-28 1995-10-20 PROCESS FOR THE PREPARATION OF SOLID PHARMACEUTICAL DOSAGE FORMS
MX9602514A MX9602514A (en) 1994-10-28 1995-10-20 Process for preparing solid pharmaceutical dosage forms.
AU37028/95A AU3702895A (en) 1994-10-28 1995-10-20 Process for preparing solid pharmaceutical dosage forms
AT95934712T ATE198150T1 (en) 1994-10-28 1995-10-20 METHOD FOR PRODUCING SOLID PHARMACEUTICAL DOSAGE FORM
DE69519664T DE69519664T2 (en) 1994-10-28 1995-10-20 METHOD FOR PRODUCING SOLID PHARMACEUTICAL DOSAGE FORM
DK95934712T DK0737065T3 (en) 1994-10-28 1995-10-20 Process for the preparation of solid pharmaceutical dosage forms
ZA959073A ZA959073B (en) 1994-10-28 1995-10-26 Process for preparing solid pharmaceutical dosage forms
GR20010400012T GR3035194T3 (en) 1994-10-28 2001-01-10 Process for preparing solid pharmaceutical dosage forms
JP2005370451A JP2006111635A (en) 1994-10-28 2005-12-22 Process for preparing solid pharmaceutical dosage form

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/330,936 US5738875A (en) 1994-10-28 1994-10-28 Process for preparing solid pharmaceutical dosage forms
CA002134611A CA2134611C (en) 1994-10-28 1994-10-28 Process for preparing solid pharmaceutical dosage forms
GB9421837A GB9421837D0 (en) 1994-10-28 1994-10-28 Process for preparing solid pharmaceutical dosage forms
PCT/GB1995/002486 WO1996013252A1 (en) 1994-10-28 1995-10-20 Process for preparing solid pharmaceutical dosage forms

Publications (2)

Publication Number Publication Date
CA2134611A1 CA2134611A1 (en) 1996-04-29
CA2134611C true CA2134611C (en) 2002-12-24

Family

ID=27169885

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002134611A Expired - Lifetime CA2134611C (en) 1994-10-28 1994-10-28 Process for preparing solid pharmaceutical dosage forms

Country Status (16)

Country Link
US (1) US5738875A (en)
EP (1) EP0737065B1 (en)
JP (2) JP3839845B2 (en)
CN (1) CN1204877C (en)
AT (1) ATE198150T1 (en)
AU (1) AU3702895A (en)
CA (1) CA2134611C (en)
DE (1) DE69519664T2 (en)
DK (1) DK0737065T3 (en)
ES (1) ES2153498T3 (en)
GB (1) GB9421837D0 (en)
GR (1) GR3035194T3 (en)
MX (1) MX9602514A (en)
PT (1) PT737065E (en)
WO (1) WO1996013252A1 (en)
ZA (1) ZA959073B (en)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2134611C (en) * 1994-10-28 2002-12-24 Richard John Yarwood Process for preparing solid pharmaceutical dosage forms
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
GB9702799D0 (en) * 1997-02-12 1997-04-02 Scherer Corp R P Process for preparing solid pharmaceutical dosage forms
US20040023948A1 (en) * 1997-03-24 2004-02-05 Green Richard David Fast-dispersing dosage form containing 5-HT1 agonists
US5976577A (en) * 1997-07-11 1999-11-02 Rp Scherer Corporation Process for preparing fast dispersing solid oral dosage form
DE19821625C1 (en) * 1998-05-15 2000-01-05 Merck Patent Gmbh Pharmaceutical preparation
BR0007360A (en) * 1999-12-23 2001-08-14 Johnson & Johnson Controlled release composition
US20030119916A1 (en) * 2000-03-01 2003-06-26 David Fowler Treatment of functional gastrointestinal disorders
US6814978B2 (en) * 2000-12-29 2004-11-09 Mcneil-Ppc, Inc. Process for preparing a soft tablet
CA2449731A1 (en) * 2001-06-07 2002-12-19 Tanabe Seiyaku Co., Ltd. Functional grain-containing preparations quickly disintegrated in the oral cavity
HUP0401022A3 (en) * 2001-08-14 2006-11-28 Biotie Therapies Corp Method for the preparation of pharmaceutical compositions containing opioid antagonist for treating alcoholism or alcohol abuse
CA2461042A1 (en) * 2001-09-25 2003-04-03 Ashish Madan Process for the preparation of fast dissolving dosage form
EP1438030A2 (en) * 2001-09-28 2004-07-21 McNEIL-PPC, INC. Modified release dosage forms
US9358214B2 (en) * 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
AU2003211051A1 (en) * 2002-02-13 2003-09-04 Michael K. Weibel Drug dose-form and method of manufacture
WO2003077842A2 (en) * 2002-03-12 2003-09-25 Bristol-Myers Squibb Company Palatable oral suspension and method
US20040001885A1 (en) * 2002-06-27 2004-01-01 Unchalee Kositprapa Rapidly disintegrating antihistamine formulation
US7985422B2 (en) * 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US8367111B2 (en) * 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
US20040234579A1 (en) * 2003-05-22 2004-11-25 Mark D. Finke, Inc. Dietary supplements and methods of preparing and administering dietary supplements
US20050036977A1 (en) * 2003-08-11 2005-02-17 Dilip Gole Taste-masked resinate and preparation thereof
CN1863517B (en) * 2003-10-07 2011-08-03 安壮奇制药公司 Rapidly disintegrating formulation
EP2322196A2 (en) 2003-11-10 2011-05-18 Reprise Biopharmaceutics, LLC Pharmaceutical compositions including low dosages of desmopressin
DE20321887U1 (en) 2003-11-10 2012-01-20 Allergan, Inc. Medicines comprising low doses of desmopressin
EP1582221A1 (en) 2004-03-31 2005-10-05 Chiesi S.A. Pharmaceutical oral compositions with a taste masking effect
US8545881B2 (en) 2004-04-19 2013-10-01 Eurand Pharmaceuticals, Ltd. Orally disintegrating tablets and methods of manufacture
US8747895B2 (en) * 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
ES2409347T3 (en) * 2004-10-21 2013-06-26 Aptalis Pharmatech, Inc. Pharmaceutical compositions of masked flavor with gastro-soluble porogenic agents
US20060105038A1 (en) * 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
ITMI20042356A1 (en) * 2004-12-10 2005-03-10 Acraf ORODISPERSIBLE PHARMACEUTICAL COMPOSITION AND PROCEDURE FOR PREPARING IT
US8697674B2 (en) * 2004-12-29 2014-04-15 Naturon, Inc. Xanthurenic acid derivative pharmaceutical compositions and methods related thereto
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
GB0516604D0 (en) * 2005-08-12 2005-09-21 Sandoz Ag Rapidly dispersing/disintegrating compositions
US7811604B1 (en) 2005-11-14 2010-10-12 Barr Laboratories, Inc. Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same
WO2007143674A2 (en) * 2006-06-05 2007-12-13 Verus Pharmaceuticals, Inc. Methods for buccal, lingual or sublingual dosing regimens of epinephrine for the treatment of allergic emergencies
TW200817049A (en) * 2006-06-05 2008-04-16 Verus Pharmaceuticals Inc Epinephrine dosing regimens comprising buccal, lingual or sublingual and injectable dosage forms
WO2011026080A1 (en) 2009-08-31 2011-03-03 Wilmington Pharmaceuticals, Llc Fast disintegrating compositions of meloxicam, processes for preparation, and use to treat arthritis and/or pain
WO2011067667A2 (en) 2009-12-02 2011-06-09 Eurand Pharmaceuticals Limited Fexofenadine microcapsules and compositions containing them
US20110212171A1 (en) * 2010-01-08 2011-09-01 Eurand, Inc. Taste masked topiramate composition and an orally disintegrating tablet comprising the same
US10548839B2 (en) 2010-03-16 2020-02-04 Wei Tian Process of manufacturing a lyophilized fast dissolving, multi-phasic dosage form
WO2012075455A2 (en) 2010-12-02 2012-06-07 Aptalis Pharmatech, Inc. Rapidly dispersing granules, orally disintegrating tablets and methods
US9511028B2 (en) 2012-05-01 2016-12-06 Johnson & Johnson Consumer Inc. Orally disintegrating tablet
US9339489B2 (en) 2013-03-15 2016-05-17 Aprecia Pharmaceuticals Company Rapid disperse dosage form containing levetiracetam
ES2908292T3 (en) 2013-03-15 2022-04-28 Aprecia Pharmaceuticals LLC Three-dimensional printing method
JP6466399B2 (en) 2013-03-15 2019-02-06 アプレシア・ファーマスーティカルズ・カンパニー Topiramate rapidly dispersible dosage form
AU2014228063B2 (en) 2013-03-15 2017-04-20 Aprecia Pharmaceuticals LLC Rapidly dispersible dosage form of oxcarbazepine
MX368159B (en) 2014-01-10 2019-09-20 Johnson & Johnson Consumer Inc Process for making tablet using radiofrequency and lossy coated particles.
RU2706727C2 (en) 2014-09-17 2019-11-20 Стирлайф Индия Прайвит Лимитед Effervescent compositions and methods for production and use thereof
US11219594B2 (en) 2015-12-12 2022-01-11 Steerlife India Private Limited Effervescent compositions of metformin and processes for preparation thereof
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
IT201600078683A1 (en) * 2016-07-27 2018-01-27 Mattia Saporiti EDIBLE MATRIX FOR VETERINARY AND ZOOTECHNICAL USE AND RELATED PRODUCTION METHOD
WO2018115888A1 (en) 2016-12-21 2018-06-28 N4 Pharma Uk Limited Novel formulations of aprepitant
US10493026B2 (en) 2017-03-20 2019-12-03 Johnson & Johnson Consumer Inc. Process for making tablet using radiofrequency and lossy coated particles
EP3883546A1 (en) 2018-11-21 2021-09-29 Rosemont Pharmaceuticals Ltd Oral topiramate suspension formulations with extended shelf stability and enhanced bioavailability
ES2966816T3 (en) 2019-02-22 2024-04-24 Catalent Uk Swindon Zydis Ltd Minimization of agglomeration, aeration and coating preservation of pharmaceutical compositions comprising ibuprofen
ES2961850T3 (en) * 2019-02-22 2024-03-14 Catalent Uk Swindon Zydis Ltd Minimization of suspension aeration during in-line mixing
CN113453662A (en) 2019-02-22 2021-09-28 康特伦英国斯温顿捷迪斯有限公司 Minimizing agglomeration of drug particle coating materials during storage to stabilize disintegration time of drug products
GB2585411B (en) 2019-02-22 2023-10-04 Catalent Uk Swindon Zydis Ltd Preserving functionally-coated API particles produced by solventless mixing processes in aqueous suspension
CA3183295A1 (en) 2020-06-26 2021-12-30 Jaedeok Yoo Rapidly-orodispersible tablets having an interior cavity
TW202220638A (en) 2020-07-31 2022-06-01 英商康泰倫特英國斯文敦載迪斯有限公司 Pharmaceutical compositions comprising coated api
WO2022179635A1 (en) * 2021-02-27 2022-09-01 北京兴源联合医药科技有限公司 β-NICOTINAMIDE MONONUCLEOTIDE FREEZE-DRIED ORAL PREPARATION

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE45770B1 (en) * 1976-10-06 1982-11-17 Wyeth John & Brother Ltd Pharmaceutical dosage forms
GB1548022A (en) * 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
CA1097233A (en) * 1977-07-20 1981-03-10 George K. E. Gregory Packages
IE53696B1 (en) * 1981-12-02 1989-01-18 Wyeth John & Brother Ltd Solid shaped articles
GB2111423B (en) * 1981-12-02 1985-06-26 Wyeth John & Brother Ltd Making quick-dissolving pills
GB8528195D0 (en) * 1985-11-15 1985-12-18 Boots Co Plc Therapeutic compositions
US5206025A (en) * 1989-05-24 1993-04-27 Rhone-Poulenc Sante Porous pharmaceutical form and its preparation
US5079018A (en) * 1989-08-14 1992-01-07 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
US5039540A (en) * 1989-08-14 1991-08-13 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
US5215756A (en) * 1989-12-22 1993-06-01 Gole Dilip J Preparation of pharmaceutical and other matrix systems by solid-state dissolution
US5188825A (en) * 1989-12-28 1993-02-23 Iles Martin C Freeze-dried dosage forms and methods for preparing the same
BR9205864A (en) * 1991-04-08 1994-06-28 Sumitomo Pharma Porous solid formulations containing physiologically active proteinaceous substances.
EP0651997B1 (en) * 1991-12-24 1998-10-28 Yamanouchi Pharmaceutical Co. Ltd. Intrabuccally disintegrating preparation and production thereof
US5298261A (en) * 1992-04-20 1994-03-29 Oregon Freeze Dry, Inc. Rapidly distintegrating tablet
JPH06298668A (en) * 1993-02-18 1994-10-25 Takeda Chem Ind Ltd Pharmaceutical composition for oral administration
US5382437A (en) * 1993-10-25 1995-01-17 Hunter Research Corporation Frozen liquified gas composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
CA2134611C (en) * 1994-10-28 2002-12-24 Richard John Yarwood Process for preparing solid pharmaceutical dosage forms

Also Published As

Publication number Publication date
ZA959073B (en) 1996-05-22
DK0737065T3 (en) 2001-01-15
JPH09511256A (en) 1997-11-11
CN1204877C (en) 2005-06-08
US5738875A (en) 1998-04-14
GB9421837D0 (en) 1994-12-14
JP3839845B2 (en) 2006-11-01
ES2153498T3 (en) 2001-03-01
GR3035194T3 (en) 2001-04-30
DE69519664T2 (en) 2001-05-17
MX9602514A (en) 1997-05-31
WO1996013252A1 (en) 1996-05-09
CA2134611A1 (en) 1996-04-29
ATE198150T1 (en) 2001-01-15
AU3702895A (en) 1996-05-23
JP2006111635A (en) 2006-04-27
EP0737065B1 (en) 2000-12-20
DE69519664D1 (en) 2001-01-25
EP0737065A1 (en) 1996-10-16
PT737065E (en) 2001-04-30
CN1140407A (en) 1997-01-15

Similar Documents

Publication Publication Date Title
CA2134611C (en) Process for preparing solid pharmaceutical dosage forms
US5827541A (en) Process for preparing solid pharmaceutical dosage forms of hydrophobic substances
US5837287A (en) Process for preparing solid pharmaceutical dosage forms
JP2550362B2 (en) Spray dried acetaminophen
US5976577A (en) Process for preparing fast dispersing solid oral dosage form
JP2542400B2 (en) Spray dried acetaminophen
JP4129995B2 (en) Pharmaceutical composition for rapid suspension in an aqueous medium
WO2002047607A2 (en) Process for the preparation of a fast dissolving dosage form
US20020098198A1 (en) Oral drug delivery system
JP2550363B2 (en) Spray dried acetaminophen
IE45770B1 (en) Pharmaceutical dosage forms
RO112990B1 (en) SOLID DOSAGE FORM
JPH0753662B2 (en) Pharmaceutical preparation and method for producing the same
US6726928B2 (en) Process for preparing solid dosage forms for unpalatable pharmaceuticals
KR950014442B1 (en) Spray dried acetaminophen
KR100355060B1 (en) How to prepare a solid pharmaceutical dosage form

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20141028